GLP-1 weight-loss calculator
US$ 21.08
eli lilly retatrutide lawsuit asks to join over compounded versions of its weight-loss drugs Lilly stays ahead of the
Description
An examination of pharmacy- and medical-claims data from 2021 for 4,066 nondiabetic GLP-1 users with obesity found 53.7 percent discontinued use within 180 days, and 67.7 percent stopped within a year
Even in these cases, escalation schedules were applied, meaning that individuals did not simply jump into the higher tiers
No automated refills
In another study, Salaga et al
10.1038/sj.ijo.0803344 111
